专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1990004785A1 PROVISION OF DENSITY SPECIFIC BLOOD CELLS FOR THE STRUCTUREDNESS OF THE CYTOPLASMIC MATRIX (SCM) TEST 审中-公开
标题翻译：密度特异性血细胞提供CYTOPLASMIC MATRIX（SCM）测试结构的提供
公开(公告)号：WO1990004785A1
公开(公告)日：1990-05-03
申请号：PCT/US1989004658
申请日：1989-10-17
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： G01N33/49
CPC分类号： G01N33/5094
摘要： An improved method is provided for the isolation of lymphocytes for use in the SCM test for the detection of cancer and other diseases and conditions. The method of the present invention can isolate either or both of the SCM-responding lymphocyte fractions from the same blood sample: the F2 fraction, with a buoyant density of 1.0590 g/cm to 1.0670 g/cm measured at 20 DEG C in a solution having an osmolality of about 0.315 Osm/kg, and the F4 fraction, with a buoyant density of 1.0690 g/cm to 1.0730 g/cm . These lymphocyte fractions are isolated in visible bands and are substantially free of lymphocytes having other buoyant densities. This avoids cross-contamination of the lymphocyte fractions with each other as well as with SCM non-responding lymphocytes. Several gradients useful in this isolation method are described. This isolation method can use as starting material either a blood sample depleted of phagocytic cells or the total population of lymphocytes. The latter avoids the use of iron powder or carbonyl-iron powder in removing the phagocytic cells.
摘要翻译：提供了一种用于分离淋巴细胞用于SCM检测用于检测癌症和其他疾病和病症的改进方法。本发明的方法可以从相同的血液样品中分离出一个或两个SCM反应性淋巴细胞部分：F2级分，其活力密度为1.0590g / cm 3至1.0670g / cm 3 20℃，重量克分子渗透压浓度为约0.315Om / kg，F4级分，浮力密度为1.0690g / cm 3至1.0730g / cm 3。这些淋巴细胞级分在可见条带中分离，并且基本上不含具有其它浮力密度的淋巴细胞。这避免了淋巴细胞部分彼此以及SCM无反应淋巴细胞的交叉污染。描述了在该隔离方法中有用的几个梯度。这种分离方法可以作为消耗吞噬细胞的血液样品或淋巴细胞总数的起始物质。后者避免使用铁粉或羰基铁粉去除吞噬细胞。

2. 发明申请

WO1988006595A1 GENERAL CANCER-ASSOCIATED SCM-RECOGNITION FACTOR, PREPARATION AND METHOD OF USE 审中-公开
标题翻译：一般癌相关SCM识别因子，制备和使用方法
公开(公告)号：WO1988006595A1
公开(公告)日：1988-09-07
申请号：PCT/US1988000568
申请日：1988-03-04
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： C07K07/08
CPC分类号： C07K7/08 , A61K38/00 , A61K47/6845 , C07K14/4745 , C07K16/18
摘要： A general cancer-associated SCM factor has been isolated, purified to homogeneity, and characterized, and methods for its use have been described. The SCM factor is a low molecular weight peptide able to pass through a filter with a nominal molecular weight cutoff of 1000 daltons, but not through a filter with a nominal molecular weight cutoff of 500 daltons. The filter has the approximate amino acid composition of (Asx2, Glx3, Ser, His, Gly5, Thr, Arg, Ala3, Tyr, Met, Val3, Phe3, Ile, Leu3, Lys2), and has the ability to produce at least a 10 % decrease in the intracellular fluorescein fluorescence polarization value of potentially SCM-responding lymphocytes from blood samples of donors with cancer. Tryptic peptides of fifteen and sixteen amino acids not including the amino terminus of the SCM factor have also been purified, and have SCM activity. The SCM factor can modify the SCM response of lymphocytes from donors free of cancer to the response characteristic of lymphocytes from donors afflicted with cancer. The factor can also diminish the natural in vitro cytotoxicity of killer lymphocytes toward tumor cells. A method for purifying the SCM factor from blood is described, leading to a factor purified to substantial homogeneity by reverse-phase high pressure liquid chromatography. The SCM factor is useful for screening of blood samples for the presence of malignancy in the donor by the SCM test. Methods for reducing in vivo activity of SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.
摘要翻译：一般癌症相关SCM因子已被分离，纯化至均一性，并被表征，并且已经描述了其使用方法。 SCM因子是能够通过具有1000道尔顿标称分子量截留值的过滤器的低分子量肽，但不能通过标称分子量截留值为500道尔顿的过滤器。该过滤器具有（Asx2，Glx3，Ser，His，Gly5，Thr，Arg，Ala3，Tyr，Met，Val3，Phe3，Ile，Leu3，Lys2）的近似氨基酸组成，并且具有产生至少一种来自癌症患者血液样本的潜在SCM反应淋巴细胞的细胞内荧光素荧光偏振值降低10％。未包括SCM因子氨基末端的十六，十六个氨基酸的胰蛋白酶肽也已被纯化，并具有SCM活性。 SCM因子可以将来自免受癌症的供体的淋巴细胞的SCM反应改变为患有癌症的患者的淋巴细胞的反应特征。该因子还可以减少杀伤淋巴细胞对肿瘤细胞的天然的体外细胞毒性。描述了从血液中纯化SCM因子的方法，导致通过反相高压液相色谱纯化至基本均匀的因子。 SCM因子可用于通过SCM测试筛选供体中恶性肿瘤的血液样品。用于降低SCM因子的体内活性的方法，例如透析或抗体中和，也可用于治疗癌症。

3. 发明申请

WO1989008662A1 GENERAL CANCER-ASSOCIATED SCM-RECOGNITION FACTOR, PREPARATION AND METHOD OF USE 审中-公开
标题翻译：一般癌相关SCM识别因子，制备和使用方法
公开(公告)号：WO1989008662A1
公开(公告)日：1989-09-21
申请号：PCT/US1989000961
申请日：1989-03-09
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： C07K07/08
CPC分类号： C07K7/08 , A61K38/00 , C07K14/4745 , G01N33/5091
摘要： A general cancer-associated SCM factor has been isolated, purified to homogeneity, and characterized, and methods for its use have been described. The SCM factor is a low molecular weight peptide able to pass through a filter with a nominal molecular weight cutoff of 1000 daltons, but not through a filter with a nominal molecular weight cutoff of 500 daltons. The factor has the approximate amino acid composition of (Asx2, Glx3, Ser, His, Gly5, Thr, Arg, Ala3, Tyr, Met, Val3, Phe3, Ile, Leu3, Lys2), and has the ability to produce at least a 10% decrease in the intracellular fluorescein fluorescence polarization value of potentially SCM-responding lymphocytes from blood samples of donors with cancer. Tryptic peptides of fiteen and sixteen amino acids not including the amino terminus of the SCM factor have also been purified, and have SCM activity. The SCM factor can modify the SCM response of lymphocytes from donors free of cancer to the response characteristic of lymphocytes from donors afflicted with cancer. The factor can also diminish the natural in vitro cytotoxicity of killer lymphocytes toward tumor cells. A method for purifying the SCM factor from blood is described, leading to a factor purified to substantial homogeneity by reverse-phase high pressure liquid chromatography. The SCM factor is useful for screening of blood samples for the presence of malignancy in the donor by the SCM test. Methods for reducing in vivo activity of SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.
摘要翻译：一般癌症相关SCM因子已被分离，纯化至均一性，并被表征，并且已经描述了其使用方法。 SCM因子是能够通过具有1000道尔顿标称分子量截留值的过滤器的低分子量肽，但不能通过标称分子量截留值为500道尔顿的过滤器。该因子具有（Asx2，Glx3，Ser，His，Gly5，Thr，Arg，Ala3，Tyr，Met，Val3，Phe3，Ile，Leu3，Lys2）的近似氨基酸组成，并且具有产生至少一种来自癌症患者血液样本的潜在SCM反应淋巴细胞的细胞内荧光素荧光偏振值降低10％。丝氨酸蛋白酶和不含氨基末端的16个氨基酸的胰蛋白酶肽也被纯化，并具有SCM活性。 SCM因子可以将来自免受癌症的供体的淋巴细胞的SCM反应改变为患有癌症的患者的淋巴细胞的反应特征。该因子还可以减少杀伤淋巴细胞对肿瘤细胞的天然的体外细胞毒性。描述了从血液中纯化SCM因子的方法，导致通过反相高压液相色谱纯化至基本均匀的因子。 SCM因子可用于通过SCM测试筛选供体中恶性肿瘤的血液样品。用于降低SCM因子的体内活性的方法，例如透析或抗体中和，也可用于治疗癌症。

4. 发明申请

WO1987007382A1 METHOD FOR MEASURING POLARIZED FLUORESCENCE EMISSIONS 审中-公开
标题翻译：测量极化荧光发射的方法
公开(公告)号：WO1987007382A1
公开(公告)日：1987-12-03
申请号：PCT/US1987001259
申请日：1987-05-27
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： G01N21/64
CPC分类号： G01N21/6445 , G01N21/6428 , G01N2021/6421
摘要： Method for the measurement of polarized emissions in which background emissions are compensated for without the necessity of separating a fluorescing material from a substrate which contributes the background fluorescence. The method is particularly useful in measuring fluorescence from a suspension of cells. The method involves the measurement of polarized fluorescence emissions in a vertical and a horizontal plane at a first wavelength and at a second wavelength. The second wavelength is selected based upon the bathochromic shift of the spectrum of the fluorescence emission of the background fluorescence as compared to the fluorescence of the material being analyzed at each of the wavelengths. From these measurements a factor representing the fraction of the total intensity of fluorescence emission due to background fluorescence is determined from which the intensity of the vertically and horizontally polarized emission intensities due to background fluorescence is derived. The derived polarization emission intensities are then deducted from the vertically and horizontally polarized emission intensities obtained at the first wavelength to obtain polarized emission intensities due solely to the material being analyzed. The method of the present invention is particularly adapted for the measurement of polarized fluorescent emissions from suspensions of cells in a substrate which, which substrate contributes background fluorescence.
摘要翻译：用于测量背景辐射被补偿而不需要从有助于背景荧光的衬底分离荧光材料的极化发射的方法。该方法特别可用于测量来自细胞悬浮液的荧光。该方法涉及在第一波长和第二波长的垂直和水平平面中测量偏振荧光发射。基于在每个波长处分析的材料的荧光相比，基于背景荧光的荧光发射的光谱的红移移动来选择第二波长。从这些测量中，确定表示由于背景荧光引起的荧光发射的总强度的分数的因子，由此导出由背景荧光引起的垂直和水平极化发射强度的强度。然后从在第一波长获得的垂直和水平极化发射强度中扣除导出的极化发射强度，以获得仅由于正在分析的材料而产生的极化发射强度。本发明的方法特别适用于测量底物中的细胞悬浮液的极化荧光发射，哪种底物有助于背景荧光。

5. 发明申请

WO1987005393A1 SEPARATION AND METHOD OF USE OF DENSITY SPECIFIC BLOOD CELLS 审中-公开
标题翻译：密度特异性血细胞的分离和使用方法
公开(公告)号：WO1987005393A1
公开(公告)日：1987-09-11
申请号：PCT/US1987000523
申请日：1987-03-04
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： G01N33/50
CPC分类号： G01N33/5091 , B03D3/00
摘要： Method for the detection of certain diseases and body conditions based upon the response to antigenes associated with the disease or condition tested for by lymphocytes having buoyant densities of 1.0590g/cm to 1.0670g/cm and densities of 1.0690g/cm to 1.0730g/cm in a continuous density gradient solution having an osmolality of 0.315 to 0.320 osm/kg at a temperature of 20 DEG C. The response is indicated by changes in the structure of the cytoplasmic matrix of the cell as measured by intracellular fluorescein fluorescence polarization. The lymphocytes are separated from peripheral blood by centrifugation in a continuous gradient density solution having limiting density gradients which bracket the range of buoyant densities of the lymphocytes to be separated.
摘要翻译：基于对具有1.0590g / cm 3至1.0670g / cm 3的浮力密度和1.0690g密度的淋巴细胞测试的疾病或病症的抗原的抗原的响应来检测某些疾病和身体状况的方法 / cm 3至1.0730g / cm 3，在20℃的温度下，渗透浓度为0.315〜0.320osm / kg的连续密度梯度溶液。响应由细胞质基质的结构变化通过细胞内荧光素荧光偏振测量。通过在具有限制性淋巴细胞的浮力密度范围的限制密度梯度的连续梯度密度溶液中离心将淋巴细胞与外周血分离。

6. 发明申请

WO1994003806A1 IMMUNOCHEMICAL ASSAYS FOR CANCER-ASSOCIATED SCM RECOGNITION FACTOR 审中-公开
标题翻译：癌症相关SCM识别因子的免疫化学测定
公开(公告)号：WO1994003806A1
公开(公告)日：1994-02-17
申请号：PCT/US1993007451
申请日：1993-08-09
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： G01N33/53
CPC分类号： C07K16/18 , C07K14/4745
摘要： Disclosed are antibodies to peptides active in the structuredness of the cytoplasmic matrix test (SCM-factor peptides) and to fragments of the peptides by immunization of antibody-producing animals with the peptides or fragments. Both polyclonal and monoclonal antibodies can be prepared. Particularly useful are antibodies specifically binding the peptides M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K (SEQ ID NO: 2) and F-L-M-I-D-Q-N-T-K (SEQ ID NO: 3). The antibodies can be labeled and are suitable for performing immunoassays to detect the presence of SCM cancer-recognition factors in cell cultures or body fluids. One particularly useful immunoassay can distinguish SCM factor from partially homologous peptide sequences, and comprises: (a) incubating a first aliquot of the sample with a first antibody specific for the cancer-recognition factor to bind the first antiboby to the cancer-recognition factor in the first aliquot; (b) reacting a second aliquot of the sample with a second antiboby specific for the amino-terminal portion of the partially homologous peptide sequence to bind the second antibody to the partially homologous peptide sequence in the second aliquot; and (c) comparing the quantity of the first antibody bound to the first aliquot with the quantity of the second antibody bound to the second aliquot to detect the cancer recognition factor.
摘要翻译：公开了通过用肽或片段免疫产生抗体的动物，对细胞质基质测试（SCM-因子肽）的结构化和肽段的活性的肽的抗体。可以制备多克隆和单克隆抗体。特别有用的是特异性结合肽M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-1-D-Q-N-T-K-V-P-L-F-M-G-K（SEQ ID NO：2）和F-L-M-1-D-Q-N-T-K（SEQ ID NO：3）的抗体。抗体可以被标记，并且适于进行免疫测定以检测细胞培养物或体液中SCM癌症识别因子的存在。一个特别有用的免疫测定可以区分SCM因子与部分同源肽序列，并且包括：（a）将第一等分试样与第一抗体对癌症识别因子结合，将第一抗体与癌症识别因子结合第一等份; （b）使所述样品的第二等分试样与所述部分同源肽序列的氨基末端部分特异性的第二抗体结合，以使所述第二抗体与所述第二等分试样中的部分同源肽序列结合; 和（c）将与第一等分试样结合的第一抗体的量与与第二等分试样结合的第二抗体的量进行比较以检测癌症识别因子。

7. 发明申请

WO9119736A3 CANCER-ASSOCIATED SCM-RECOGNITION FACTOR, PREPARATION AND METHOD OF USE 审中-公开
标题翻译：癌症相关SCM识别因子，准备和使用方法
公开(公告)号：WO9119736A3
公开(公告)日：1992-02-20
申请号：PCT/US9104334
申请日：1991-06-18
申请人： CERCEK BORIS , CERCEK LEA
发明人： CERCEK BORIS , CERCEK LEA
IPC分类号： A61K38/00 , A61K35/16 , A61K39/395 , A61K47/48 , A61K49/00 , A61P35/00 , C07K1/20 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/47 , C07K14/585 , C07K14/81 , C07K16/00 , C07K16/18 , C12N1/21 , C12N15/12 , C12P21/08 , G01N33/50 , G01N33/53 , G01N33/574 , A61K37/02 , C07K7/10
CPC分类号： A61K35/16 , A61K38/00 , A61K47/6845 , C07K7/08 , C07K14/4745 , C07K14/585 , C07K16/18 , G01N33/5011 , G01N33/5091 , Y10S436/811 , Y10S436/813
摘要： A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.

8. 发明申请

WO1991019736A2 CANCER-ASSOCIATED SCM-RECOGNITION FACTOR, PREPARATION AND METHOD OF USE 审中-公开
标题翻译：癌症相关SCM识别因子，准备和使用方法
公开(公告)号：WO1991019736A2
公开(公告)日：1991-12-26
申请号：PCT/US1991004334
申请日：1991-06-18
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： C07K07/08
CPC分类号： A61K35/16 , A61K38/00 , A61K47/6845 , C07K7/08 , C07K14/4745 , C07K14/585 , C07K16/18 , G01N33/5011 , G01N33/5091 , Y10S436/811 , Y10S436/813
摘要： A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.
摘要翻译：已经分离了用于实现细胞质基质（SCM）测试结构化的癌症识别因子（SCM因子），将其纯化至基本均匀，并进行了表征，并描述了其使用方法。该因子是至少9个氨基酸残基的肽，包括9个氨基酸残基的核心序列，其具有基本上等同于序列FLMIDQNTK的两亲性分布，并且产生SCM-1的细胞内荧光偏振值至少降低10％来自患有癌症的捐助者的淋巴细胞反应。表示M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K的共有序列的合成SCM因子是完全活性的。针对SCM因子的抗体可用于可以检测该因子的免疫测定，包括在体外生长的癌细胞中的检测。 SCM因子可用于筛选血液样本和其他体液或细胞抽吸物，以供应者中存在恶性肿瘤。包括癌症增殖和侵袭促进在内的SCM因子的多重作用谱，以及宿主的免疫防御机制的抑制以及癌细胞对SCM因子的合成代表了癌症管理的新靶点。降低SCM因子的体内活性，如透析或抗体中和的方法也可用于治疗癌症。

9. 发明申请

WO1989008118A1 SYNTHETIC SCM-ACTIVE CANCER RECOGNITION PEPTIDES 审中-公开
标题翻译：合成SCM活性癌基因识别肽
公开(公告)号：WO1989008118A1
公开(公告)日：1989-09-08
申请号：PCT/US1989000816
申请日：1989-03-01
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： C07K07/06
CPC分类号： C07K7/06 , A61K38/00 , C07K16/18
摘要： The SCM (structuredness of cytoplasmic matrix) test is a means of distinguishing lymphocytes isolated from mammalian donors, including humans, afflicted with cancer from lymphocytes isolated from donors free of malignancy. The test comprises contacting the lymphocytes with a challenging agent and then observing a decrease in the structuredness of the cytoplasmic matrix in lymphocytes from donors with cancer; lymphocytes from donors without cancer show no decrease in structuredness. Preferably the decrease in structuredness is quantified by mesuring the fluorescence polarization for an extrinsic fluor added to the cells and observing a decrease in fluorescence polarization after lymphocytes from a donor with cancer have been contacted with a challenging agent. Among the challenging agents useful in the SCM test are several synthetic peptides which are the subject of the present invention. These peptides, of which two have the amino acid sequences Phe-Trp-Gly-Ala-Gly-Gln-Arg (I) and Phe-Trp-Gly-Ala-Glu-Gly-Gln-Arg (II), react with lymphocytes from donors with any type of malignancy. Also among the aspects of the present invention are several other peptides expected to have SCM activity because of their close structural relationship to peptides (I) and (II), methods of using the synthetic SCM-active peptides in tests for the presence or absence of malignancy, antibodies specifically binding the synthetic peptides, including monoclonal antibodies, and genetic probes consisting of DNA sequences corresponding to the amino acid sequences of the synthetic SCM-active peptides.
摘要翻译： SCM（细胞质基质的结构化）测试是区分从哺乳动物供体（包括人）分离的淋巴细胞的一种手段，所述哺乳动物供体患有癌症，来自分离自无恶性肿瘤的供体的淋巴细胞。测试包括使淋巴细胞与挑战性试剂接触，然后观察来自具有癌症的供体的淋巴细胞中细胞质基质的结构性的降低; 来自没有癌症的供体的淋巴细胞显示结构性没有降低。优选地，结构化的降低通过对添加到细胞中的外在荧光的荧光偏振进行定量，并且观察到来自具有癌症的供体的淋巴细胞已经与挑战性试剂接触后的荧光偏振的降低。在SCM测试中有用的挑战性试剂中，有几种合成肽是本发明的主题。这些具有氨基酸序列Phe-Trp-Gly-Ala-Gly-Gln-Arg（I）和Phe-Trp-Gly-Ala-Glu-Gly-Gln-Arg（II）的肽与淋巴细胞反应来自任何类型的恶性肿瘤的供体。在本发明的方面之中还有几种预期具有SCM活性的其它肽，因为它们与肽（I）和（II）具有紧密的结构关系，在测试中使用合成的SCM-活性肽的方法是否存在恶性肿瘤，特异性结合合成肽的抗体，包括单克隆抗体，以及由对应于合成SCM活性肽的氨基酸序列的DNA序列组成的遗传探针。

10. 发明申请

WO1988003955A1 DIFFERENTIAL BINDING OF POTENTIAL SENSITIVE MATERIALS BY LYMPHOCYTES 审中-公开
标题翻译：淋巴细胞的潜在敏感材料的差异性结合
公开(公告)号：WO1988003955A1
公开(公告)日：1988-06-02
申请号：PCT/US1987003054
申请日：1987-11-20
申请人： CERCEK, Boris , CERCEK, Lea
IPC分类号： C12Q01/04
CPC分类号： G01N33/56972 , G01N33/5091 , G01N2021/6439
摘要： The method comprises contacting a suspension of viable lymphocytes with a solution containing a membrane potential sensitive fluorescent dye. The contact between the lymphocyte suspension and the MPS dye is maintained for sufficient time to permit labelling of the lymphocytes by the MPS dye material. The labelled lymphocytes are passed individually through a focused source of excitation energy causing any MPS dye material to fluoresce. The fluorescent emission from each cell is recorded as a pulse and the number of pulses of each intensity are recorded. The distribution of the number of pulses versus the intensity is bimodal. A first peak includes pulses of low fluorescence intensity and a second peak comprises pulses of high fluorescence intensity. A ratio of the total counts of low fluorescence intensity to the total counts of high fluorescence intensity produces a factor which distinguishes lymphocytes derived from bodies afflicted with malignancy from bodies which are not afflicted with malignancy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式